To achieve this, we used three NSCLC cell lines: NCI-H2228 (EML4-ALK), A549 (KRAS mutation), and HCC-78 (ROS1 rearrangement) having different genetic alterations and employing multiple techniques (flow cytometry, intracellular staining for granzyme B, cell viability assays, ELISA, RT-PCR, Western blot). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.